The tweet was deleted by the author.
But we saved everything 🙂.
Esperion Therapeutics draws attention to the recently released 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia. The discussion featured Dr. Steve Nissen and Dr. C. Michael Gibson, two prominent figures in cardiovascular medicine.
The new guidelines are expected to influence future approaches in managing cholesterol and cardiovascular risk, providing updated recommendations for clinicians and researchers. Further details on how these guidelines will impact clinical practice are anticipated.
Esperion Therapeutics recently claimed the 88th position on the Financial Times Americas Fastest Growing Companies 2026 list among 300 firms. Earlier this year, the company unveiled key data on NEXLETOL from the CLEAR Outcomes study at the ACC Annual Scientific Session 2026. These developments have placed Esperion in the spotlight during major cardiovascular events.